ZyMōt is a small microfluidic chip used during IVF to select the healthiest sperm from a semen sample. Instead of the traditional approach of spinning sperm in a centrifuge, ZyMōt lets sperm swim through a porous membrane on their own, filtering out those with the best motility and least DNA damage. It’s one of a growing number of IVF add-ons designed to improve embryo quality, and fertility clinics worldwide now offer it as an optional upgrade to standard sperm processing.
How the ZyMōt Chip Works
The device is surprisingly simple. It consists of two small wells separated by a porous membrane. A lab technician places the raw semen sample into the first well and fills the second well with a clean wash medium. The chip is then incubated at body temperature (37°C) for up to 30 minutes.
During that half hour, sperm migrate from the first well through the membrane and into the second well using only their own swimming ability. The membrane acts as a physical barrier: only sperm with strong, progressive motility can make it through. Slower, damaged, or dead sperm get left behind. At the end of incubation, the embryologist collects the fluid from the second well, which now contains a concentrated sample of the most functional sperm. Those sperm are then used for ICSI (where a single sperm is injected directly into an egg) or conventional IVF fertilization.
The entire process is passive. No centrifuge, no chemicals, no mechanical force applied to the sperm. That distinction is the core of ZyMōt’s appeal.
Why Skipping the Centrifuge Matters
Standard sperm processing in IVF typically involves density gradient centrifugation, where the sample is spun at high speed to separate healthy sperm from seminal fluid, debris, and abnormal cells. It works, but the spinning generates reactive oxygen species, which are unstable molecules that can damage sperm DNA. The more handling and centrifugation a sperm sample undergoes, the more oxidative stress accumulates.
Research published in Advanced Healthcare Materials found that microfluidic sorting produces sperm with significantly lower levels of reactive oxygen species and less DNA fragmentation compared to the traditional swim-up method. Because the sperm are never centrifuged or mechanically manipulated, they retain more of their original DNA integrity. For couples where sperm DNA damage has been identified as a potential factor in failed cycles or miscarriage, this is a meaningful difference.
What the Clinical Evidence Shows
The question most patients want answered is whether ZyMōt actually improves IVF outcomes. The evidence so far is encouraging but not definitive.
A non-inferiority trial comparing microfluidic sperm sorting to standard density gradient centrifugation found that live birth rates were numerically higher with the microfluidic approach (63.3% versus 60.9%), though the difference was not statistically significant. What did reach significance was the blastocyst formation rate: 50.3% of embryos reached the blastocyst stage with microfluidic sorting compared to 41.0% with centrifugation. That’s a notable gap, because reaching the blastocyst stage is a key milestone in embryo development and a strong predictor of implantation potential.
Additional clinical trials are underway examining whether ZyMōt-selected sperm produce embryos with better chromosomal health (ploidy). A trial registered on ClinicalTrials.gov is specifically studying whether the device reduces the rate of chromosomally abnormal embryos, which would have direct implications for miscarriage rates and the need for genetic testing of embryos.
Who Might Benefit Most
ZyMōt is offered broadly, but certain patient profiles stand to gain the most. If a semen analysis has revealed high DNA fragmentation, meaning a large percentage of sperm carry damaged genetic material, ZyMōt’s ability to select sperm with intact DNA becomes especially relevant. High sperm DNA fragmentation has been linked to poor embryo development, implantation failure, and early pregnancy loss.
Clinics also commonly recommend ZyMōt for couples with unexplained infertility, repeated IVF failures, poor embryo quality in previous cycles, or recurrent miscarriage. In these cases, sperm DNA damage may be a contributing factor that standard semen analysis parameters like count, motility, and morphology don’t capture. Even men with “normal” semen parameters can have elevated DNA fragmentation.
For patients with severely low sperm counts, ZyMōt may be less practical. The device requires a minimum number of motile sperm to yield a usable sample on the other side of the membrane. Your embryologist will assess whether the starting sample is suitable.
What It Costs
ZyMōt is typically offered as an add-on to a standard ICSI or IVF cycle. Pricing varies by clinic and country. As a reference point, Manchester Fertility in the UK charges £260 (roughly $330 USD) on top of regular ICSI fees. Most clinics price it in the $200 to $500 range, making it one of the more affordable IVF add-ons compared to options like preimplantation genetic testing or endometrial receptivity analysis.
Because it’s considered an elective add-on, insurance rarely covers the additional cost. Some clinics include it as part of premium IVF packages rather than charging separately.
What the Process Looks Like for You
If you opt for ZyMōt, nothing changes about your IVF experience as a patient. The semen sample is collected the same way (either on the day of egg retrieval or from a previously frozen sample). The only difference happens in the lab: instead of spinning the sample, the embryologist loads it into the ZyMōt chip, waits 30 minutes, and collects the sorted sperm. From there, ICSI or fertilization proceeds as usual.
You won’t need extra appointments, additional blood work, or any change to your medication protocol. The decision to use ZyMōt is typically made before the cycle begins, during your treatment planning consultation. If you’re interested, ask your clinic whether they offer it and whether your specific situation makes it a good fit based on your partner’s semen analysis and your cycle history.